N-TERMINALLY MODIFIED GLP-1 DERIVATIVES
The present invention relates to N-terminally modified derivatives of human glucagon-like peptide-1 (GLP-1) and analogues thereof having a protracted profile of action, as well as the use of such derivatives in pharmaceutical compositions for the treatment of obesity, insulin dependent or non-insuli...
Gespeichert in:
| Hauptverfasser: | , , , |
|---|---|
| Format: | Patent |
| Sprache: | eng ; fre ; ger |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | KNUDSEN, LISELOTTE, BJERRE MADSEN, KJELD HUUSFELDT, PER, OLAF NIELSEN, PER, FRANKLIN |
| description | The present invention relates to N-terminally modified derivatives of human glucagon-like peptide-1 (GLP-1) and analogues thereof having a protracted profile of action, as well as the use of such derivatives in pharmaceutical compositions for the treatment of obesity, insulin dependent or non-insulin dependent diabetes mellitus. The GLP-1 derivatives have a lipophilic substituent attached to at least one amino acid residue and are substituted at the N-terminal end with a substituent comprising an optionally substituted 5- or 6-membered ring system, e.g. an imidazole. |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_EP1062240B1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>EP1062240B1</sourcerecordid><originalsourceid>FETCH-epo_espacenet_EP1062240B13</originalsourceid><addsrcrecordid>eNrjZFD30w1xDfL19HP08YlU8PV38XTzdHVRcPcJ0DVUcHEN8gxzDPEMcw3mYWBNS8wpTuWF0twMCm6uIc4euqkF-fGpxQWJyal5qSXxrgGGBmZGRiYGTobGRCgBAJNsIzo</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>N-TERMINALLY MODIFIED GLP-1 DERIVATIVES</title><source>esp@cenet</source><creator>KNUDSEN, LISELOTTE, BJERRE ; MADSEN, KJELD ; HUUSFELDT, PER, OLAF ; NIELSEN, PER, FRANKLIN</creator><creatorcontrib>KNUDSEN, LISELOTTE, BJERRE ; MADSEN, KJELD ; HUUSFELDT, PER, OLAF ; NIELSEN, PER, FRANKLIN</creatorcontrib><description>The present invention relates to N-terminally modified derivatives of human glucagon-like peptide-1 (GLP-1) and analogues thereof having a protracted profile of action, as well as the use of such derivatives in pharmaceutical compositions for the treatment of obesity, insulin dependent or non-insulin dependent diabetes mellitus. The GLP-1 derivatives have a lipophilic substituent attached to at least one amino acid residue and are substituted at the N-terminal end with a substituent comprising an optionally substituted 5- or 6-membered ring system, e.g. an imidazole.</description><language>eng ; fre ; ger</language><subject>BEER ; BIOCHEMISTRY ; CHEMISTRY ; COMPOSITIONS THEREOF ; CULTURE MEDIA ; ENZYMOLOGY ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; MICROBIOLOGY ; MICROORGANISMS OR ENZYMES ; MUTATION OR GENETIC ENGINEERING ; ORGANIC CHEMISTRY ; PEPTIDES ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS ; SPIRITS ; VINEGAR ; WINE</subject><creationdate>2010</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20100428&DB=EPODOC&CC=EP&NR=1062240B1$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,780,885,25563,76418</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20100428&DB=EPODOC&CC=EP&NR=1062240B1$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>KNUDSEN, LISELOTTE, BJERRE</creatorcontrib><creatorcontrib>MADSEN, KJELD</creatorcontrib><creatorcontrib>HUUSFELDT, PER, OLAF</creatorcontrib><creatorcontrib>NIELSEN, PER, FRANKLIN</creatorcontrib><title>N-TERMINALLY MODIFIED GLP-1 DERIVATIVES</title><description>The present invention relates to N-terminally modified derivatives of human glucagon-like peptide-1 (GLP-1) and analogues thereof having a protracted profile of action, as well as the use of such derivatives in pharmaceutical compositions for the treatment of obesity, insulin dependent or non-insulin dependent diabetes mellitus. The GLP-1 derivatives have a lipophilic substituent attached to at least one amino acid residue and are substituted at the N-terminal end with a substituent comprising an optionally substituted 5- or 6-membered ring system, e.g. an imidazole.</description><subject>BEER</subject><subject>BIOCHEMISTRY</subject><subject>CHEMISTRY</subject><subject>COMPOSITIONS THEREOF</subject><subject>CULTURE MEDIA</subject><subject>ENZYMOLOGY</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>MICROBIOLOGY</subject><subject>MICROORGANISMS OR ENZYMES</subject><subject>MUTATION OR GENETIC ENGINEERING</subject><subject>ORGANIC CHEMISTRY</subject><subject>PEPTIDES</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><subject>SPIRITS</subject><subject>VINEGAR</subject><subject>WINE</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2010</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZFD30w1xDfL19HP08YlU8PV38XTzdHVRcPcJ0DVUcHEN8gxzDPEMcw3mYWBNS8wpTuWF0twMCm6uIc4euqkF-fGpxQWJyal5qSXxrgGGBmZGRiYGTobGRCgBAJNsIzo</recordid><startdate>20100428</startdate><enddate>20100428</enddate><creator>KNUDSEN, LISELOTTE, BJERRE</creator><creator>MADSEN, KJELD</creator><creator>HUUSFELDT, PER, OLAF</creator><creator>NIELSEN, PER, FRANKLIN</creator><scope>EVB</scope></search><sort><creationdate>20100428</creationdate><title>N-TERMINALLY MODIFIED GLP-1 DERIVATIVES</title><author>KNUDSEN, LISELOTTE, BJERRE ; MADSEN, KJELD ; HUUSFELDT, PER, OLAF ; NIELSEN, PER, FRANKLIN</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_EP1062240B13</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; fre ; ger</language><creationdate>2010</creationdate><topic>BEER</topic><topic>BIOCHEMISTRY</topic><topic>CHEMISTRY</topic><topic>COMPOSITIONS THEREOF</topic><topic>CULTURE MEDIA</topic><topic>ENZYMOLOGY</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>MICROBIOLOGY</topic><topic>MICROORGANISMS OR ENZYMES</topic><topic>MUTATION OR GENETIC ENGINEERING</topic><topic>ORGANIC CHEMISTRY</topic><topic>PEPTIDES</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><topic>SPIRITS</topic><topic>VINEGAR</topic><topic>WINE</topic><toplevel>online_resources</toplevel><creatorcontrib>KNUDSEN, LISELOTTE, BJERRE</creatorcontrib><creatorcontrib>MADSEN, KJELD</creatorcontrib><creatorcontrib>HUUSFELDT, PER, OLAF</creatorcontrib><creatorcontrib>NIELSEN, PER, FRANKLIN</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>KNUDSEN, LISELOTTE, BJERRE</au><au>MADSEN, KJELD</au><au>HUUSFELDT, PER, OLAF</au><au>NIELSEN, PER, FRANKLIN</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>N-TERMINALLY MODIFIED GLP-1 DERIVATIVES</title><date>2010-04-28</date><risdate>2010</risdate><abstract>The present invention relates to N-terminally modified derivatives of human glucagon-like peptide-1 (GLP-1) and analogues thereof having a protracted profile of action, as well as the use of such derivatives in pharmaceutical compositions for the treatment of obesity, insulin dependent or non-insulin dependent diabetes mellitus. The GLP-1 derivatives have a lipophilic substituent attached to at least one amino acid residue and are substituted at the N-terminal end with a substituent comprising an optionally substituted 5- or 6-membered ring system, e.g. an imidazole.</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | eng ; fre ; ger |
| recordid | cdi_epo_espacenet_EP1062240B1 |
| source | esp@cenet |
| subjects | BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS THEREOF CULTURE MEDIA ENZYMOLOGY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY MICROBIOLOGY MICROORGANISMS OR ENZYMES MUTATION OR GENETIC ENGINEERING ORGANIC CHEMISTRY PEPTIDES PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS SPIRITS VINEGAR WINE |
| title | N-TERMINALLY MODIFIED GLP-1 DERIVATIVES |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T21%3A30%3A13IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=KNUDSEN,%20LISELOTTE,%20BJERRE&rft.date=2010-04-28&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EEP1062240B1%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |